Health Care [ 9/12 ] | Biotechnology [ 47/73 ]
NASDAQ | Common Stock
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications.
It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), SanofiS. A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates.
The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.
Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 8, 25 | -0.67 Increased by +11.84% | -0.76 Increased by +12.00% |
| Feb 13, 25 | -0.75 Increased by +2.60% | -0.67 Decreased by -12.12% |
| Oct 11, 24 | -0.67 Increased by +1.47% | -0.71 Increased by +5.63% |
| Jul 11, 24 | -0.71 Decreased by -57.78% | -0.63 Decreased by -12.70% |
| Apr 10, 24 | -0.76 Decreased by -1.33% | -0.80 Increased by +5.00% |
| Feb 15, 24 | -0.77 Increased by +11.49% | -0.57 Decreased by -35.09% |
| Oct 12, 23 | -0.68 Increased by +24.44% | -0.76 Increased by +10.53% |
| Jul 13, 23 | -0.45 Increased by +55.45% | -0.56 Increased by +19.64% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Feb 28, 25 | 18.45 M Increased by +11.26% | -56.35 M Decreased by -35.73% | Decreased by -305.38% Decreased by -21.99% |
| Nov 30, 24 | 13.28 M Decreased by -12.37% | -58.55 M Decreased by -39.55% | Decreased by -440.75% Decreased by -59.25% |
| Aug 31, 24 | 12.59 M Decreased by -31.84% | -48.96 M Decreased by -32.38% | Decreased by -388.91% Decreased by -94.20% |
| May 31, 24 | 12.09 M Decreased by -60.58% | -44.55 M Decreased by -104.44% | Decreased by -368.39% Decreased by -418.65% |
| Feb 29, 24 | 16.59 M Increased by +30.74% | -41.52 M Decreased by -17.50% | Decreased by -250.33% Increased by +10.13% |
| Nov 30, 23 | 15.16 M Increased by +123.49% | -41.96 M Decreased by -0.60% | Decreased by -276.77% Increased by +54.99% |
| Aug 31, 23 | 18.47 M Increased by +71.13% | -36.98 M Increased by +17.27% | Decreased by -200.26% Increased by +51.66% |
| May 31, 23 | 30.68 M Increased by +168.33% | -21.79 M Increased by +51.67% | Decreased by -71.03% Increased by +81.99% |